Clinical trial results:
A feasibility study to assess the effects of AntiretroViral Intensification with Cenicriviroc for the management of HIV-associated Cognitive Impairment. The AVICCI study

Summary

EudraCT number	2015-002955-85
Trial protocol	GB
Global end of trial date	06 January 2017

Results information

Result version number	v1 (current)
This version publication date	14 October 2018
First version publication date	14 October 2018
Summary attachment (see zip file)	Cenicriviroc cerebrospinal fluid exposure abstract (Cenicriviroc CSF abstract 22 sep 18 EudraCT.pdf)

Trial information

Trial identification

Sponsor protocol code	AVICCI001

Additional study identifiers

ISRCTN number	ISRCTN18166185
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-
Other trial identifiers	The AVICCI study: AVICCI01

Notes:

Sponsors

Sponsor organisation name	Imperial College London
Sponsor organisation address	Praed Street, London, United Kingdom,
Public contact	Legg, Imperial College London, 44 02033121464, k.legg@imperial.ac.uk
Scientific contact	Legg, Imperial College London, 44 02033121464, k.legg@imperial.ac.uk

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	05 July 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	06 January 2017
Global end of trial reached?	Yes
Global end of trial date	06 January 2017
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the acceptability, safety and tolerability of cART intensification with cenicriviroc in PLWH with cognitive impairment

Protection of trial subjects:

Cerebral magnetic resonance imaging to ensure no imaging contraindications to cerebrospinal fluid examination

Background therapy:

On cART comprising of BHIVA guideline recommended therapies (2015 guidelines) with the exception of elvitegravir/cobicistat and rilpivirine

Evidence for comparator:

No comparator

Actual start date of recruitment	29 January 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 7
Worldwide total number of subjects	7
EEA total number of subjects	7

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	7
From 65 to 84 years	0

85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Of seven subjects enrolled, four completed all study procedures.

Pre-assignment

Screening details:

Screening period lasted 28 days prior to the baseline visit.

Pre-assignment period milestones

Number of subjects started	7
Intermediate milestone: Number of subjects	Baseline visit: 7
Number of subjects completed	7

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

Open label

Arms

Arm title	Treatment

Arm description:

Addition of cenicriviroc

Arm type	Experimental
Investigational medicinal product name	Cenicriviroc
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

ART with enzyme inhibition properties	Cenicriviroc dose
Darunavir/ritonavir 800/100 mg daily, Darunavir / ritonavir 600/100 mg twice daily Atazanavir 300/100 mg daily	Total dose 50 mg in morning with food 2 x 25 mg tablet

Administration with ART agents with minimal effects on hepatic iso-enzymes:

ART	Cenicriviroc dose
Dolutegravir 50 mg daily, Dolutegravir 50 mg twice daily, Raltegravir 400 mg twice daily	Total dose 150 mg in morning with food 1 x 150 mg tablet

Administration with ART agents with enzyme induction properties:

ART	Cenicriviroc dose
Efavirenz 600 mg daily	Total dose 300 mg in morning with food 2 x 150mg tablet

Number of subjects in period 1	Treatment
Started	7
Baseline visit	7
Completed	4
Not completed	3
Adverse event, non-fatal	3

Baseline characteristics

Reporting groups	
Reporting group title	Overall trial

Reporting group description: -

Reporting group values	Overall trial	Total	
Number of subjects	7	7	
Age categorical			
Male median age 45			
Units: Subjects			
Age continuous			
Median 45 IQR 42-49			
Units: years			
median	45		
inter-quartile range (Q1-Q3)	42 to 49	-	
Gender categorical			
All male			
Units: Subjects			
Female	0	0	
Male	7	7	

End points

End points reporting groups

Reporting group title	Treatment
Reporting group description: Addition of cenicriviroc	

Primary: CSF Cenicriviroc concentration

End point title	CSF Cenicriviroc concentration[1]
End point description: Lumber puncture performed for CSF collection	
End point type	Primary
End point timeframe: 8 weeks	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive endpoint only.

End point values	Treatment			
Subject group type	Reporting group			
Number of subjects analysed	4			
Units: ng/ml				
geometric mean (confidence interval 95%)				
CSF Cenicriviroc exposure	0.43 (0.28 to 0.68)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information	
Timeframe for reporting adverse events:	
From first participant first visit to last participant last visit	
Adverse event reporting additional description:	
Fatigue, headache, nausea	
Assessment type	Systematic

Dictionary used	
Dictionary name	SNOMED CT
Dictionary version	RF2

Reporting groups	
Reporting group title	Participants
Reporting group description:	
Participants enrolled on the study	

Serious adverse events	Participants		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 7 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Participants		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 7 (42.86%)		
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 7 (14.29%)		
occurrences (all)	1		
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	1 / 7 (14.29%)		
occurrences (all)	1		
Metabolism and nutrition disorders			
Fatigue			

subjects affected / exposed occurrences (all)	3 / 7 (42.86%) 3		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

All results are descriptive only.

Notes: